Liposomal Grb-2: Additional Phase I data

Data from 6 evaluable patients with advanced acute myelogenous leukemia (AML) in cohorts 7 and 8 of a dose-escalation Phase I trial showed that twice-weekly IV 60 or 90 mg/m 2 BP001 plus low-dose cyta...